Roche bags full control of Foundation Medicine in $2.4B follow-up buyout
Whatever Foundation Medicine has been doing since Roche threw its weight behind an R&D collaboration three years ago, both partners are liking it. And now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.